Belantamab mafodotin monotherapy for relapsed or refractory multiple myeloma: a real-world observational study in the United States

Affiliations

¹ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY. hultcram@mskcc.org.
² Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY.
³ Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO.
⁴ Hematology Department, University Hospital of Leon, Leon.
⁵ Department of Hematology, Catholic University of Leuven, Leuven.
⁶ Value, Evidence and Outcomes, GSK, Upper Providence, PA.
⁷ Global Medical Affairs, GSK, Zug.
⁸ Real World Study Delivery, GSK, Stevenage.
⁹ Real World Data Strategy and Partnerships, Value, Evidence and Outcomes, GSK, Collegeville, PA.
¹⁰ Groupe d'Analyse, Ltee., Montreal, Quebec.
¹¹ Analysis Group, Inc., Boston, MA.
¹² IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Universita degli Studi di Bologna, Bologna.
¹³ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

Malin Hultcrantz et al. Haematologica. 2025.

. 2025 Mar 1;110(3):753-757.

doi: 10.3324/haematol.2024.285893.

¹ Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NY. hultcram@mskcc.org.
² Flaum Eye Institute, University of Rochester Medical Center, Rochester, NY.
³ Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO.
⁴ Hematology Department, University Hospital of Leon, Leon.
⁵ Department of Hematology, Catholic University of Leuven, Leuven.
⁶ Value, Evidence and Outcomes, GSK, Upper Providence, PA.
⁷ Global Medical Affairs, GSK, Zug.
⁸ Real World Study Delivery, GSK, Stevenage.
⁹ Real World Data Strategy and Partnerships, Value, Evidence and Outcomes, GSK, Collegeville, PA.
¹⁰ Groupe d'Analyse, Ltee., Montreal, Quebec.
¹¹ Analysis Group, Inc., Boston, MA.
¹² IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seragnoli", Universita degli Studi di Bologna, Bologna.
¹³ Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.

No abstract available

References

1. Tai YT, Mayes PA, Acharya C, et al. . Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128-3138. - PMC - PubMed
1. US Food and Drug Administration. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma. 2020; https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grant.... Accessed November 16, 2023.
1. Lonial S, Lee HC, Badros A, et al. . Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207-221. - PubMed
1. European Medicines Agency. EMA recommends non-renewal of authorisation of multiple myeloma medicine Blenrep. 2023; https://www.ema.europa.eu/en/news/ema-recommends-non-renewal-authorisati.... Accessed January 11, 2024.
1. US Food and Drug Administration. Announcement of the revocation of the biologics license for BLENREP. 2023; https://www.govinfo.gov/content/pkg/FR-2023-03-30/pdf/2023-06576.pdf. Accessed December 11. 2023.